

# University of Washington Presenters at ISPOR, 2015, Philadelphia, Pennsylvania

**Sunday, May 17, 2015**

**ISPOR Student Research Competition**

**6:30-8:30PM**

**Grand Ballroom, Salon C-D (Level 5)**

**UW TEAM: Blythe Adamson, Will Canestaro, Meng Li & Solomon Lubinga**

## **Plenaries**

**Monday, May 18, 2015**

8:40-8:50AM

Grand Ballroom, Salon A-F (Level 5)

**Meeting Program Overview & Awards Session**

Lou Garrison, PhD

**Tuesday, May 19, 2015**

8:30-10:30AM

Grand Ballroom, Salon A-F (Level 5)

**SECOND PLENARY SESSION: COST-EFFECTIVENESS AND CLINICAL PRACTICE  
GUIDELINES: HAVE WE REACHED A TIPPING POINT?**

***Moderator:*** Lou Garrison, PhD

**Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy,  
University of Washington, Seattle, WA, USA**

## **WORKSHOPS**

**Monday, May 18**

W1

5:00-6:00pm

Grand Ballroom, Salon A, B, F (Level 5)

**PATIENT-CENTERED BENEFIT-RISK ANALYSIS: REGULATORY DEVELOPMENTS AND PROSPECTS**

**Discussion Leaders:** F. Reed Johnson, PhD, Senior Research Scholar, Duke Clinical Research Institute,  
Duke University, Durham, NC, USA

John F.P. Bridges, PhD, Associate Professor, Department of Health Policy and Management and International  
Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

**Lou Garrison, PhD**, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of

Pharmacy, University of Washington, Seattle, WA, USA [bio](#)

Bennett Levitan, MD, PhD, Director, Epidemiology, Janssen Research & Development, LLC, Titusville, NJ, USA

## PODIUMS

### Monday, May 18

#### HM: HEALTH CARE MANAGEMENT STUDIES

##### HM4

3:00 PM - 3:15 PM

Room: Grand Ballroom, Salon H (Level 5)

#### HOW MUCH EVIDENCE DO WE NEED BEFORE IMPLEMENTING PHARMACOGENOMIC TESTING IN THE CLINIC?

Guzauskas GF, Serbin M, Veenstra DL

University of Washington, Seattle, WA, USA

#### CS: RESEARCH ON COST STUDIES METHODS

##### CS3

3:45PM–4:45PM

Room: Grand Ballroom, Salon H (Level 5)

#### CURE MODELS: ACCOUNTING FOR CURED PATIENTS IN ECONOMIC EVALUATIONS

Othus M<sup>1</sup>, **Bansal A**<sup>2</sup>, Koepf L<sup>1</sup>, Wagner S<sup>3</sup>, Ramsey S<sup>1</sup>

<sup>1</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA, <sup>2</sup>University of Washington, Seattle, WA, USA,

<sup>3</sup>Bristol-Myers Squibb, Washington Crossing, PA, USA

#### CN: CANCER OUTCOMES RESEARCH STUDIES

##### CN2

4:00 PM - 4:15 PM

Room: Grand Ballroom, Salon A, B, F (Level 5)

#### A COMPARATIVE COST UTILITY ANALYSIS FOR FIRST LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

Carlson JJ<sup>1</sup>, Slejko JF<sup>2</sup>, Goertz H<sup>3</sup>, **Veenstra DL**<sup>1</sup>

<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>University of Maryland, Baltimore, MD, USA, <sup>3</sup>Genentech, South San Francisco, CA, USA

#### HT: HEALTH TECHNOLOGY ASSESSMENT STUDIES

##### HT2

4:00 PM - 4:15 PM

Room: Grand Ballroom, Salon G (Level 5)

#### APPLICATION OF COST-EFFECTIVENESS LOGIC TO US MANAGED CARE DRUG FORMULARIES: LONG TERM OUTCOMES OF A VALUE-BASED FORMULARY

Yeung K<sup>1</sup>, Basu A<sup>2</sup>, Hansen RN<sup>1</sup>, Watkins J<sup>3</sup>, Sullivan SD<sup>2</sup>

<sup>1</sup>School of Pharmacy, University of Washington, Seattle, WA, USA, <sup>2</sup>University of Washington, Seattle, WA, USA, <sup>3</sup>Premera Blue Cross, Mountlake Terrace, WA, USA

## **HE: HEALTH CARE EXPENDITURE STUDIES**

### **HE4**

4:30 PM - 4:45 PM

Room: Grand Ballroom, Salon C, D, E (Level 5)

## **OPTIMIZING CANCER CLINICAL TRIALS RESEARCH INVESTMENT DECISIONS IN THE UNITED STATES: A PROOF OF CONCEPT PORTFOLIO MANAGEMENT EVALUATION**

**Bennette CS<sup>1</sup>**, Roth JA<sup>2</sup>, Basu A<sup>1</sup>, Carlson JJ<sup>1</sup>, Ramsey S<sup>2</sup>, Veenstra DL<sup>1</sup>

<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA

## **POSTERS**

### **MONDAY, MAY 18**

## **PRM: RESEARCH ON METHODS**

### **PRM63**

8:30AM–2:15PM May 18, 2015

Room: Franklin Hall (Level 4)

## **FEASIBILITY AND ACCEPTABILITY OF MINIMAL MODELING VALUE OF INFORMATION ANALYSES FOR REAL-TIME PRIORITIZATION DECISIONS WITHIN A LARGE CANCER CLINICAL TRIALS COOPERATIVE GROUP**

**Bennette CS<sup>1</sup>**, Veenstra DL<sup>1</sup>, Basu A<sup>1</sup>, Ramsey S<sup>2</sup>, Carlson JJ<sup>1</sup>

<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA

## **PDB: DIABETES/ENDOCRINE DISORDERS**

### **PDB96**

8:30AM–2:15PM May 18, 2015

Room: Franklin Hall (Level 4)

## **FINANCING A CURE FOR DIABETES IN A MULTI-PAYER ENVIRONMENT**

**Basu A<sup>1</sup>**, Kamal-Bahl S<sup>2</sup>, Subedi P<sup>3</sup>

<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Pfizer, Philadelphia, PA, USA, <sup>3</sup>Pfizer, New York, NY, USA

## **PDB: DIABETES/ENDOCRINE DISORDERS**

### **PDB100**

8:30AM–2:15PM May 18, 2015

Room: Franklin Hall (Level 4)

## **USE OF HEDIS A1C TARGETS IN CHARACTERIZING TREATMENT GOALS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATING BASAL INSULIN**

**Oster G<sup>1</sup>**, Moen D<sup>2</sup>, Yang T<sup>3</sup>, Dalal M<sup>3</sup>, Kazemi M<sup>3</sup>, Sung JC<sup>3</sup>, Traylor L<sup>3</sup>, **Sullivan SD<sup>4</sup>**

<sup>1</sup>Policy Analysis Inc., Brookline, MA, USA, <sup>2</sup>MoenMDConsulting, St Paul, MN, USA, <sup>3</sup>Sanofi US, Inc., Bridgewater, NJ, USA, <sup>4</sup>University of Washington School of Pharmacy, Seattle, WA, USA

## **PMD: MEDICAL DEVICE/DIAGNOSTICS**

### **PMD51**

8:30AM–2:15PM May 18, 2015  
Room: Franklin Hall (Level 4)

**ESTIMATING THE COST-EFFECTIVENESS OF LEFT ATRIAL APPENDAGE CLOSURE COMPARED TO WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION**

**Shih V**, Devine B  
University of Washington, Seattle, WA, USA

**PHP: HEALTH CARE USE & POLICY STUDIES**  
**PHP37**

3:45PM–7:45PM May 18, 2015  
Room: Franklin Hall (Level 4)

**A FRAMEWORK FOR STRENGTHENING PHARMACEUTICAL MANUFACTURING IN SUB-SAHARAN AFRICA**

**Mann M**<sup>1</sup>, Adamson BJ<sup>1</sup>, Rennie T<sup>2</sup>, Stergachis A<sup>1</sup>  
<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>University of Namibia, Windhoek, Namibia

**PHP: HEALTH CARE USE & POLICY STUDIES**  
**PHP59**

3:45PM–7:45PM May 18, 2015  
Room: Franklin Hall (Level 4)

**WHEN IS HEALTH ECONOMICS AND OUTCOMES RESEARCH EVIDENCE IMPORTANT TO U.S. PAYERS?**

**Bajaj PS**<sup>1</sup>, Willke RJ<sup>2</sup>, Basu A<sup>1</sup>, Sullivan SD<sup>1</sup>, Garrison LP<sup>1</sup>  
<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Pfizer, Inc., New York, NY, USA

**PHP: HEALTH CARE USE & POLICY STUDIES**  
**PHP82**

3:45PM–7:45PM May 18, 2015  
Room: Franklin Hall (Level 4)

**IMPACT OF CLINICAL AND HEALTH ECONOMIC PUBLICATIONS ON COMMERCIAL SUCCESS OF PHARMACEUTICAL PRODUCTS IN THE U.S**

**Slejko JF**<sup>1</sup>, Basu A<sup>2</sup>, Sullivan SD<sup>3</sup>  
<sup>1</sup>University of Maryland School of Pharmacy, Baltimore, MD, USA, <sup>2</sup>University of Washington, Seattle, WA, USA, <sup>3</sup>University of Washington School of Pharmacy, Seattle, WA, USA

**PIH: INDIVIDUAL'S HEALTH**  
**PIH19**

3:45PM–7:45PM May 18, 2015  
Room: Franklin Hall (Level 4)

**IMPLICATIONS OF EMPLOYER COVERAGE OF CONTRACEPTION: COST-EFFECTIVENESS OF CONTRACEPTION UNDER AN EMPLOYER MANDATE**

**Canestaro WJ**, Vodicka E, Downing D  
University of Washington, Seattle, WA, USA

**PIH: INDIVIDUAL'S HEALTH**  
**PIH55**

3:45PM–7:45PM May 18, 2015  
Room: Franklin Hall (Level 4)

**FACTORS IMPACTING PERSONALIZED MEDICINE TEST ADOPTION: EVALUATING PATIENT PREFERENCES AND WILLINGNESS TO PAY**

**Canestaro WJ<sup>1</sup>**, Regier DA<sup>2</sup>, Veenstra DL<sup>1</sup>, Lavallee D<sup>1</sup>, Basu A<sup>1</sup>, Carlson JJ<sup>1</sup>

<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Canadian Centre for Applied Research in Cancer Control (ARCC), British Columbia Cancer Agency, Vancouver, BC, Canada

**PMH: MENTAL HEALTH**

**PMH38**

3:45PM–7:45PM May 18, 2015

Room: Franklin Hall (Level 4)

**A COST-EFFECTIVENESS ANALYSIS OF ANTIPSYCHOTICS FOR TREATMENT OF SCHIZOPHRENIA IN UGANDA**

**Lubinga SJ<sup>1</sup>**, Mutamba BB<sup>2</sup>, Nganizi A<sup>3</sup>, Babigumira JB<sup>1</sup>

<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Butabika National Referral Hospital for Mental, Neurological and Substance Abuse Disorders, Kampala, Uganda, <sup>3</sup>Kadic Hospital, Kampala, Uganda

**PMH: MENTAL HEALTH**

**PMH39**

3:45PM–7:45PM May 18, 2015

Room: Franklin Hall (Level 4)

**ESTIMATING THE COST-EFFECTIVENESS OF VORTIOXETINE VERSUS DESVENLAFAXINE AS FIRST LINE THERAPY FOR MILD TO MODERATE MAJOR DEPRESSIVE DISORDER IN REMITTED PATIENTS**

**Keyloun KR**, Devine B

University of Washington, Seattle, WA, USA

**PORPP/ISPOR Alumni & Friends Reception**

**5:00-8:00PM Monday, May 18**

**McGillin's Olde Ale House**

**1310 Drury Street**

**Philadelphia, PA**

**Tuesday, May 19**

**Issue Panels III**

2:15-3:15pm

Room: Grand Ballroom, Salon A, B, F (Level 5)

IP11

**THE \$2.6 BILLION QUESTION: WHY ARE DRUG DEVELOPMENT COSTS RISING AND CAN WE AFFORD IT?** (Invited Issue Panel)

Moderator: **Lou Garrison, PhD**, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA [bio](#)

**POSTERS**

**PRS: RESPIRATORY-RELATED DISORDERS**

**PRS3**

8:30AM–2:15PM May 19, 2015

Room: Franklin Hall (Level 4)

**MORTALITY AND READMISSION IN MECHANICALLY VENTILATED PATIENTS WITH PNEUMONIA**

**Hansen RN<sup>1</sup>**, Black DJ<sup>1</sup>, Joish VN<sup>2</sup>, Spilsbury-Cantalupo M<sup>2</sup>, Sullivan SD<sup>1</sup>

<sup>1</sup>University of Washington School of Pharmacy, Seattle, WA, USA, <sup>2</sup>Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA

**PSS: SENSORY SYSTEMS DISORDERS**

**PSS26**

8:30AM–2:15PM May 19, 2015

Room: Franklin Hall (Level 4)

**ESTIMATING COST-EFFECTIVE DEVICE PRICES FOR PEDIATRIC COCHLEAR IMPLANTATION IN INDIA** **Drennan WR**, Banerjee S, Garrison L, University of Washington, Seattle, WA, USA

**PMS: MUSCULAR-SKELETAL DISORDERS**

**PMS48**

8:30AM–2:15PM May 19, 2015

Room: Franklin Hall (Level 4)

**COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE MANAGEMENT OF INADEQUATELY RESPONDING RHEUMATOID ARTHRITIS PATIENTS**

**Hansen RN<sup>1</sup>**, Best JH<sup>2</sup>, Sullivan SD<sup>3</sup>, Carlson JJ<sup>3</sup>

<sup>1</sup>School of Pharmacy, University of Washington, Seattle, WA, USA, <sup>2</sup>Genentech, Inc, South San Francisco, CA, USA, <sup>3</sup>University of Washington, Seattle, WA, USA

**PRS: RESPIRATORY-RELATED DISORDERS**

**PRS5**

8:30AM–2:15PM May 19, 2015

Room: Franklin Hall (Level 4)

**DRUG THERAPY FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS**

**Canestaro WJ<sup>1</sup>**, Forrester S<sup>2</sup>, Ho L<sup>1</sup>, Devine B<sup>1</sup>

<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Group Health Cooperative, Seattle, WA, USA

**PCV: CARDIOVASCULAR DISORDERS**

**PCV52**

8:30AM–2:15PM May 19, 2015

Room: Franklin Hall (Level 4)

**ESTIMATING THE COST OF ILLNESS OF GIANT CELL ARTERITIS**

**Babigumira JB<sup>1</sup>**, Li M<sup>1</sup>, Boudreau DM<sup>1</sup>, Best JH<sup>2</sup>, Garrison LP<sup>1</sup>

<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Genentech, Inc, South San Francisco, CA, USA

**PSS: SENSORY SYSTEMS DISORDERS**

**PSS15**

8:30AM–2:15PM May 19, 2015

Room: Franklin Hall (Level 4)

**COMPARING TOTAL AND DISEASE SPECIFIC HEALTHCARE COSTS FOR GLAUCOMA PATIENTS BEFORE AND AFTER THEIR INDEX DIAGNOSIS: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS**

**Yep T<sup>1</sup>**, Patel V<sup>1</sup>, Slejko JF<sup>2</sup>, Devine B<sup>3</sup>

<sup>1</sup>Allergan, Inc, Irvine, CA, USA, <sup>2</sup>University of Maryland School of Pharmacy, Baltimore, MD, USA, <sup>3</sup>University of Washington, Seattle, WA, USA

**PIN: INFECTION**

**PIN53**

3:45PM–7:45PM May 19, 2015

Room: Franklin Hall (Level 4)

**COST-EFFECTIVENESS ANALYSIS OF A PARTIALLY EFFECTIVE HIV VACCINE IN SAN FRANCISCO**

**Adamson BJ<sup>1</sup>**, Bounthavong M<sup>2</sup>, Kublin JG<sup>3</sup>, Garrison L<sup>1</sup>

<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Univer, SEATTLE, WA, USA, <sup>3</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA

**PCN: CANCER**

**PCN44**

3:45PM–7:45PM May 19, 2015

Room: Franklin Hall (Level 4)

**THE COSTS OF CANCER-RELATED ABSENTEEISM: A SYSTEMATIC REVIEW OF THE LITERATURE**

**Yu JS<sup>1</sup>**, Carlson JJ<sup>1</sup>, University of Washington, Seattle, WA, USA, <sup>2</sup>Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA

**PCN: CANCER**

**PCN79**

3:45PM–7:45PM May 19, 2015

Room: Franklin Hall (Level 4)

**IDELALISIB PLUS RITUXIMAB VERSUS PLACEBO PLUS RITUXIMAB FOR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA: A COST-EFFECTIVENESS ANALYSIS**

**Yu JS<sup>1</sup>**, Seal B<sup>2</sup>, Carlson JJ<sup>1</sup>

<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA

**PCN: CANCER**

**PCN90**

3:45PM–7:45PM May 19, 2015

Room: Franklin Hall (Level 4)

**COST-EFFECTIVENESS OF A BIOPSY-BASED 8-PROTEIN PROGNOSTIC ASSAY TO OPTIMIZE TREATMENT DECISIONS IN GLEASON 3+3 AND 3+4 PROSTATE CANCER**

**Roth JA<sup>1</sup>**, Ramsey S<sup>1</sup>, Carlson JJ<sup>2</sup>

<sup>1</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA, <sup>2</sup>University of Washington, Seattle, WA, USA

**PCN: CANCER**

**PCN117**

3:45PM–7:45PM May 19, 2015

Room: Franklin Hall (Level 4)

**INCLUSION OF PATIENT-REPORTED OUTCOME MEASURES IN REGISTERED CLINICAL TRIALS: EVIDENCE FROM CLINICALTRIALS.GOV (2007-2013)**

**Vodicka E**<sup>1</sup>, Kim K<sup>1</sup>, Devine B<sup>1</sup>, Gnanasakthy A<sup>2</sup>, Scoggins J<sup>3</sup>, Patrick DL<sup>1</sup>

<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>RTI Health Solutions, Research Triangle Park, NC, USA,

<sup>3</sup>IMPAQ International, LLC, Columbia, MD, USA

## **PGI: GASTROINTESTINAL DISORDERS**

### **PGI1**

3:45PM–7:45PM May 19, 2015

Room: Franklin Hall (Level 4)

### **AN EVALUATION OF CLINICAL REMISSION AND SAFETY AMONG BIOLOGICS FOR MODERATE-TO-SEVERE CROHNS DISEASE: A BAYESIAN NETWORK META-ANALYSIS**

**Bounthavong M**<sup>1</sup>, Bae YH<sup>2</sup>, Vanness DJ<sup>3</sup>, Kazerooni R<sup>4</sup>, Devine B<sup>5</sup>

<sup>1</sup>Univer, SEATTLE, WA, USA, <sup>2</sup>WESTERN UNIVERSITY OF HEALTH SCIENCES, POMONA, CA, USA,

<sup>3</sup>University of Wisconsin-Madison, Madison, WI, USA, <sup>4</sup>Veterans Affairs San Diego Healthcare System, San Diego, CA, USA, <sup>5</sup>University of Washington, Seattle, WA, USA

## **PGI: GASTROINTESTINAL DISORDERS**

### **PGI18**

3:45PM–7:45PM May 19, 2015

Room: Franklin Hall (Level 4)

### **A COST-UTILITY ANALYSIS OF BIOLOGICS FOR MODERATE-TO-SEVERE CROHN'S DISEASE: EVIDENCE SYNTHESIS USING A BAYESIAN NETWORK META-ANALYSIS**

**Bounthavong M**<sup>1</sup>, Bae YH<sup>2</sup>, Devine B<sup>3</sup>, Veenstra DL<sup>3</sup>

<sup>1</sup>Univer, SEATTLE, WA, USA, <sup>2</sup>WESTERN UNIVERSITY OF HEALTH SCIENCES, POMONA, CA, USA,

<sup>3</sup>University of Washington, Seattle, WA, USA

## **Wednesday, May 20**

### **Workshops IV**

#### **W22**

1:45-2:45pm

Grand Ballroom, Salon H (Level 5)

### **HOW TO DESIGN AN ANALYTIC STRATEGY FOR EVIDENCE GENERATION FOR DECISION MAKERS**

**Discussion Leaders: Sean D. Sullivan, PhD**, Professor & Dean, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

**Omar Dabbous, MD, MPH**, Head of Quantitative Sciences, Payer Evidence Group, GlaxoSmithKline, King of Prussia, PA, USA

**Lou Garrison, PhD**, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA [bio](#)



**Rafael Alfonso-Cristancho, MD, PhD, MSc**, Director, Value Evidence Analytics, Research and Development, GlaxoSmithKline (GSK), King of Prussia, PA, USA

## **Workshops V**

### **W29**

3:00-4:00pm

Grand Ballroom, Salon G (Level 5)

### **STRATEGIES FOR ASSESSING THE PATIENT-LEVEL ECONOMIC IMPACT OF CANCER DIAGNOSIS**

**Discussion Leaders: Veena Shankaran, MD, MS**, Assistant Professor, Division of Medical Oncology, University of Washington, Seattle, WA, USA

**Amy Davidoff, PhD, MS**, Senior Research Scientist, Cancer Prevention and Control, Yale School of Public Health, New Haven, CT, USA

**Donatus Ekwueme, PhD**, Senior Health Economist, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Chamblee, GA, USA

## **POSTERS**

### **PHS: HEALTH SERVICES**

#### **PHS2**

8:30AM–2:45PM May 20, 2015

Room: Franklin Hall (Level 4)

### **SENTINEL SITE ACTIVE SURVEILLANCE OF THE SAFETY OF FIRST-LINE ANTIRETROVIRAL MEDICINES IN NAMIBIA**

**Mann M<sup>1</sup>**, Mengistu A<sup>2</sup>, Gaeseb J<sup>3</sup>, Sagwa E<sup>4</sup>, Mazibuko G<sup>4</sup>, Garrison LP<sup>1</sup>, Stergachis A<sup>1</sup>

<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Therapeutics Information and Pharmacovigilance Centre Namibia, Windhoek, Namibia, <sup>3</sup>Ministry of Health and Social Services Namibia, Windhoek, Namibia,

<sup>4</sup>Management Sciences for Health, Windhoek, Namibia

### **PSY: SYSTEMIC DISORDERS/CONDITIONS**

#### **PSY56**

8:30AM–2:45PM May 20, 2015

Room: Franklin Hall (Level 4)

### **SYSTEMATIC REVIEW OF THE PATTERNS OF USE, CHARACTERISTICS, AND QUALITY OF PATIENT REPORTED OUTCOME MEASURES IN CELIAC DISEASE**

**Canestaro WJ**, Edwards TC, Patrick DL

University of Washington, Seattle, WA, USA